Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV at Jefferies Healthcare Conference Transcript

Jun 10, 2022 / 04:45PM GMT
Release Date Price: €13
Maury Raycroft
Jefferies, LLC - Analyst

Hi everyone, my name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies, and I'm happy to introduce our guest today, Bill Lundberg, the CEO of Merus. Thanks so much for joining us today, Bill.

Bill Lundberg
Merus N.V. - President, CEO & Principal Financial Officer, Executive Director

Thanks, Maury. Appreciate your support, appreciate the support from the entire team.

Questions & Answers

Maury Raycroft
Jefferies, LLC - Analyst

And we're going to do a fireside chat today. So maybe to start off, for those who are new to the story, if you can give a one-minute intro highlighting your main products and key catalyst [act].

Bill Lundberg
Merus N.V. - President, CEO & Principal Financial Officer, Executive Director

Merus is a Dutch company, originally focused on making bispecific and multi-specific antibodies for cancer therapy. Our technology is based on a common light chain platform, and that gives

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot